Cryoport earnings
WebFeb 15, 2024 · NASHVILLE, Tennessee, February 15, 2024 - Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlledsupply chain solutions to the life sciences industry focused on the pharmaceutical and cell and gene therapy markets, today announced that the Company will report … WebMay 4, 2024 · Cryoport Revenue Climbs to $53.3 Million for First Quarter 2024 - Revenue increased 445% compared with Q1 2024, with acquisitions of MVE Biological Solutions and CRYOPDP driving significant...
Cryoport earnings
Did you know?
WebFeb 23, 2024 · CryoPort, Inc., which belongs to the Zacks Transportation - Services industry, posted revenues of $60.36 million for the quarter ended December 2024, … WebApr 5, 2024 · Cryoport (NASDAQ:CYRX) has a market capitalization of $1.03 billion and generates $237.28 million in revenue each year. The consumer goods maker earns $-37,330,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis.
WebNov 8, 2024 · Cryoport ( NASDAQ:CYRX) Third Quarter 2024 Results Key Financial Results Revenue: US$60.5m (up 6.7% from 3Q 2024). Net loss: US$7.32m (loss narrowed by 14% from 3Q 2024). US$0.15 loss per share... WebApr 13, 2024 · Cryoport Trading Down 1.5 %. The company has a debt-to-equity ratio of 0.76, a current ratio of 14.79 and a quick ratio of 14.11. The company’s fifty day moving average is $21.92 and its 200-day ...
WebApr 10, 2024 · UBS bewertet die Aktie positiv mit einem Kauf-Rating. Der Zielpreis wurde nach oben korrigiert und liegt nun bei 26 USD gegenüber zuvor 24 USD. 12 April 2024
WebFeb 15, 2024 · Cryoport, Inc. (Nasdaq: CYRX), is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene …
WebApr 11, 2024 · Cryoport also has a robust pipeline of clients developing C> treatments, supporting a total of 654 active trials. Of these, 275 (or 42%) are in Phase 1, 300 (46%) are in Phase 2, and 79 (12%) are ... hospitalisation usicWebFeb 23, 2024 · Cryoport delivered a solid finish to 2024 with total revenue of $237.3 million, led by a 24% revenue increase from Cryoport Systems and driven by the demand for our comprehensive set of... hospitalisierung hessen rkiWebApr 10, 2024 · Cryoport also has a robust pipeline of clients developing C> treatments, supporting a total of 654 active trials. Of these, 275 (or 42%) are in Phase 1, 300 (46%) … hospitaliserWebNov 8, 2024 · Cryoport ( NASDAQ:CYRX) Third Quarter 2024 Results Key Financial Results Revenue: US$60.5m (up 6.7% from 3Q 2024). Net loss: US$7.32m (loss … hospitalisierung dänemarkWebApr 9, 2024 · Equities analysts anticipate that Cryoport, Inc. will post -0.66 earnings per share for the current year. Insider Activity In related news, insider Mark W. Sawicki sold 1,362 shares of Cryoport ... hospitalisation uzWebFeb 23, 2024 · CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -14.29% and 4.10%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock? hospitalisesWebApr 11, 2024 · SWOT Analysis for Cryoport. Strength. Debt is well covered by earnings. Weakness. No major weaknesses identified for CYRX. Opportunity. Forecast to reduce losses next year. Has sufficient cash runway for more than 3 years based on current free cash flows. Trading below our estimate of fair value by more than 20%. Threat hospitalisation vaud